AbbVie reports HCV combo results

AbbVie Inc. (NYSE:ABBV) and partner Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) reported new data from studies of a three direct-acting-antiviral (3-DAA) regimen of ABT-450 plus ombitasvir ( ABT-267), dasabuvir ( ABT-333) and the booster Norvir ritonavir in difficult-to-treat populations with chronic HCV infection.

In the Phase II portion of the Phase II/III TURQUOISE-I trial, patients co-infected with HCV genotype 1 and HIV-1 receiving 12- and 24-week courses of the 3-DAA regimen plus ribavirin achieved 93.5% and 90.6% SVR12 rates. ...